Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Northfield Lab(NFLD) -- Ignore unavailable to you. Want to Upgrade?

To: Frank Wechsler who wrote (76)	8/6/1998 10:43:00 AM
From: Frank Wechsler	Read Replies (1) \| Respond to of 148

Second article: (this seems very impressive) biz.yahoo.com Wednesday August 5, 2:45 pm Eastern Time Blood substitute test in trauma patients a success CHICAGO, Aug 5 (Reuters) - A blood substitute was found to be just as effective as donated blood in providing life-sustaining oxygen to organs and tissues in the first direct comparison of seriously injured, bleeding trauma patients, according to a study reported on Wednesday. The August issue of the Journal of the American College of Surgeons reported that 44 trauma patients received either the blood substitute known as PolyHeme or donated red blood cells to replace the blood they were losing. PolyHeme, made from the hemoglobin in unused human donor blood, was developed by Northfield Laboratories Inc. (NFLD - news), of Evanston, Ill. Surgeons in three university-based trauma centers found that six units of the blood substitute could be given safely to trauma patients as their initial blood replacement. Patients receiving PolyHeme had no serious or unexpected adverse side effects. The substitute reduced by nearly half the amount of donated blood the patients needed, according to the study. Blood substitutes are being developed to ease shortages of donated blood. Unlike donated blood, they do not need to be cross-matched and they can be stored for long periods of